Anteris Technologies Announces First Patients Treated in DurAVR(R) THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies Announces First Patients Treated in DurAVR(R) THV Global Pivotal Trial (the “PARADIGM Trial”) GlobeNewswire October 27, 2025 MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge […]